Edward Tenthoff
Stock Analyst at Piper Sandler
(2.34)
# 2,629
Out of 5,012 analysts
178
Total ratings
42.11%
Success rate
-0.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $3.50 | +242.86% | 2 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $304 → $449 | $457.68 | -1.90% | 14 | Aug 1, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $6.97 | +115.21% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $2.57 | +94.93% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $75.60 | +38.89% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.88 | +127.27% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.70 | +311.76% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $9.50 | -5.26% | 4 | May 29, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $9.59 | +46.06% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.59 | +238.90% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $15.02 | +219.57% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $20.15 | +19.11% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $31.87 | +144.78% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $12.47 | +140.58% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $36.56 | +23.09% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $27.65 | +149.55% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $11.00 | +490.91% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.65 | +357.52% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.70 | +1,076.47% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.55 | +93.55% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.88 | +241.53% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $7.89 | +102.79% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.54 | +289.61% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.04 | +145.10% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $56.76 | -1.34% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $29.22 | +748.73% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.30 | +2,627.27% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $19.65 | +816.03% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $18.51 | +137.71% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.65 | +327.75% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.72 | +37,860,365.12% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $804.80 | -56.01% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.73 | +7,703.47% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $417.77 | -22.68% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $38.79 | -7.19% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.08 | +2,214.81% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.88 | +7,878.72% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.72 | +191,566.67% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $572.09 | - | 11 | Feb 13, 2017 |
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $3.50
Upside: +242.86%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $304 → $449
Current: $457.68
Upside: -1.90%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $6.97
Upside: +115.21%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $2.57
Upside: +94.93%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $75.60
Upside: +38.89%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.88
Upside: +127.27%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.70
Upside: +311.76%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $9.50
Upside: -5.26%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $9.59
Upside: +46.06%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.59
Upside: +238.90%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $15.02
Upside: +219.57%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $20.15
Upside: +19.11%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $31.87
Upside: +144.78%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $12.47
Upside: +140.58%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $36.56
Upside: +23.09%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $27.65
Upside: +149.55%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $11.00
Upside: +490.91%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $7.65
Upside: +357.52%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.70
Upside: +1,076.47%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.55
Upside: +93.55%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.88
Upside: +241.53%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $7.89
Upside: +102.79%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.54
Upside: +289.61%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $2.04
Upside: +145.10%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $56.76
Upside: -1.34%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $29.22
Upside: +748.73%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.30
Upside: +2,627.27%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $19.65
Upside: +816.03%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $18.51
Upside: +137.71%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.65
Upside: +327.75%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.72
Upside: +37,860,365.12%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $804.80
Upside: -56.01%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.73
Upside: +7,703.47%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $417.77
Upside: -22.68%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $38.79
Upside: -7.19%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.08
Upside: +2,214.81%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.88
Upside: +7,878.72%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.72
Upside: +191,566.67%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $572.09
Upside: -